The initial aim of the collaboration is to pursue a comprehensive and systematic approach to identify and develop physiological mechanisms and targets that regulate beta cell replication.
Evotec CSO Cord Dohrmann said they are enthusiastic about exploring new mechanisms that have the potential to restore beta cell function and produce first-in-class therapeutics for the treatment of diabetes in collaboration with Harvard and HHMI.